Company Performance Metrics
- Scott W. Rairigh: Executive Vice President of Corporate DevelopmentPast Role: Bristol-Myers Squibb, Executive Director , Precision Medicine and Diagnostics
- Christopher Witowski: Co-Founder and CEOPast Role: AltMed, Senior Director, Research and Development
Psilera develops therapies aimed at neurological and psychiatric disorders by leveraging neuroplastogens, compounds that promote brain plasticity without hallucinogenic effects. The company builds a proprietary library of serotonergic compounds and applies computational tools to design molecules for conditions such as alcohol use disorder and
frontotemporal dementia. Its research pipeline emphasizes non-hallucinogenic derivatives of psychedelic compounds to provide safe and scalable treatment options. Psilera integrates medicinal chemistry, neuroscience, and pharmacology to create small-molecule drugs that address unmet medical needs. Through this approach, the company seeks to expand treatment possibilities for patients facing hard-to-treat neurological conditions.
